Fosfomycin trometamol: A review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria

Drugs

Volumn 73, Issue 17, 2013, Pages 1951-1966

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFUROXIME AXETIL; COTRIMOXAZOLE; FOSFOMYCIN TROMETAMOL; NITROFURANTOIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; ASYMPTOMATIC BACTERIURIA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; PREGNANCY; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BACTERIURIA; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; FEMALE; FOSFOMYCIN; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; URINARY TRACT INFECTIONS;

EID: 84892582295     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0143-y     Document Type: Article

References (130)

1. Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011;84(7):771-6.
2. Hooton TM. Uncomplicated urinary tract infection. N Engl J Med. 2012;366(11):1028-37.
3. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-20.
4. Naber KG, Schito G, Botto H, et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008;54(5):1164-75.
5. Kahan FM, Kahan JS, Cassidy PJ, et al. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974;235:364-86.
6. Ferrari V, Bonanomi L, Borgia M. A new fosfomycin derivative with much improved bioavailability by oral route. Chemiotera-pia Antimicrobica. 1981;4(1):59-63.
7. Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection. 1990;18(Suppl 2):65-9.
8. Zambon Italia s.r.l. Monuril (fosfomycin trometamol): Italian summary of product characteristics; 2012.
9. Pierre Fabre Pharma GmbH. Monuril (fosfomycin trometamol): German summary of product characteristics; 2013.
10. Zambon S.p.A. Monuril (fosfomycin trometamol): Irish summary of product characteristics; 2011. http://www.imb.ie/images/uploaded/swedocuments/ LicenseSPC-PA1441-002-002- 05022013144045.pdf (Accessed 27 Sep 2013).
11. Zambon Switzerland Ltd. Monurol (fosfomycin tromethamine): US prescribing information; 2011. http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/ 050717s007lbl.pdf (Accessed 27 Sep 2013).
12. Garau J. Other antimicrobials of interest in the era of extended-spectrum ß-lactamases: fosfomycin, nitrofurantoin and tigecy-cline. Clin Microbiol Infect. 2008;14(Suppl 1):198-202.
13. Gelfand M, Johnson R. Single-dose fosfomycin tromethamine: evaluation in the treatment of uncomplicated lower urinary tract infection. Adv Ther. 1997;14(2):49-63.
14. Salvador T, Portugal M, Sancho L, et al. In vitro activity of fosfomycin against enterobacterial urinary isolates producing extended-spectrum ß-lactamase (ESBL) [abstract no. R2611]. 23rd European Congress of Clinical Microbiology; 27-30 Apr 2013; Berlin.
15. Demir T, Buyukguclu T. Evaluation of in vitro activity of fosfomycin tromethamin against Escherichia coli and Klebsiella species recovered from community-and hospital-acquired uirinary tract infections in Turkey [abstract no. R2572]. 23rd European Congress of Clinical Microbiology; 27-30 Apr 2013; Berlin.
16. Oliva A, Furustrand Tafin U, Betrisey B, et al. Prevention of in vitro emergence of fosfomycin resistance in methicillin-resistant Staphylococcus aureus (MRSA) [abstract no. P1595 plus poster]. 23rd European Congress of Clinical Microbiology; 27-30 Apr 2013; Berlin.
17. Ceran N, Adaleti R, Nakipoglu Y, et al. In vitro susceptibility of quinolone-resistant Escherichia coli isolates with and without producing extended-spectrum beta-lactamase to fosfomycin trometamol [abstract plus poster]. 19th European Conference of Clinical Microbiology and Infectious Diseases; 16-19 May 2009; Helsinki.
18. Karlowsky JA, Adam HJ, Baxter MR, et al. In vitro activity of fosfomycin against urinary tract isolates of Escherichia coli isolated from patients across Canada from 2010 to 2013 [abstract]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 Sept 2013; Denver (CO).
19. Pogue JM, Marchaim D, Kaye D, et al. Revisiting 'older' antimicrobials in the era of multidrug resistance. Pharmacotherapy. 2011;31(9):912-21.
20. Karageorgopoulos DE, Wang R, Yu X-H, et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Anti-microb Chemother. 2012;67(2):255-68.
21. de Cueto M, López L, Hernández JR, et al. In vitro activity of fosfomycin against extended-spectrum-b-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemo-ther. 2006;50(1):368-70.
22. Barry AL, Pfaller MA, Fuchs PC, et al. Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine. Eur J Clin Microbiol Infect Dis. 1993;12(5):352-6.
23. Liu H-Y, Lin H-C, Lin Y-C, et al. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Esche-richia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect. 2011;44(5):364-8.
24. Biondo CM, Rocha JL, Tuon FF. Fosfomycin in vitro resistance of Escherichia coli from the community. Br J Infect Dis. 2011;15(1):96.
25. Araj GF, Jaber FA. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. Leban Med J. 2012;60(3):142-7.
26. Maraki S, Samonis G, Rafailidis PI, et al. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Che-mother. 2009;53(10):4508-10.
27. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents. 2012;39(1):45-51.
28. Butcu M, Akcay SS, Inan AS, et al. In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics. J Infect Chemother. 2011;17(4):575-8.
29. Hutley EJ, Chand MA, Hounsome G, et al. Fosfomycin: an oral agent for urinary infection caused by extended spectrum beta-lactamase producing organisms. J Infect. 2010;60(4):308-9.
30. Pullukçu H, Aydemir S, Işikgöz Taşbakan I, et al. Is there a rise in resistance rates to fosfomycin and other commonly used antibiotics in Escherichia coli-mediated urinary tract infections? A perspective for 2004-2011. Turk J Med Sci. 2013;43(4):537-41.
31. Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community-and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis. 2013. doi:10. 1016/j.ijid.2013.04.005.
32. Gobernado M, Valdés L, Alós JI, et al. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain. Rev Esp Quimioter. 2007;20(1):68-76.
33. Ko KS, Suh JY, Peck KR, et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum b-lacta-mase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis. 2007;58(1):111-5.
34. Bonfiglio G, Mattina R, Lanzafame A, et al. Fosfomycin tro-methamine in uncomplicated urinary tract infections: a clinical study. Chemotherapy. 2005;51(2-3):162-6.
35. García García MI, Muñoz Bellido JL, García Rodríguez JA. In vitro susceptibility of community-acquired urinary tract pathogens to commonly used antimicrobial agents in Spain: a comparative multicenter study (2002-2004). J Chemother. 2007;19(3):263-70.
36. Knottnerus BJ, Nys S, ter Riet G, et al. Fosfomycin trometha-mine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? J Antimicrob Chemother. 2008;62(2):356-9.
37. Gismondo MR, Romeo MA, Lo Bue AM, et al. Microbiological basis for the use of fosfomycin trometamol as single-dose therapy for simple cystitis. Chemioterapia. 1986;5(4):278-82.
38. Mazzei T, Cassetta MI, Fallani S, et al. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents. 2006;28(Suppl 1):35-41.
39. Fadda G, Cattani P, Rossi A, et al. At atlas of photographs illustrating the effects of fosfomycin trometamol on bacterial adhesiveness; 2006. http://www.gimmoc.it/editoria/quaderni/quaderni-2006/q3-2006.pdf (Accessed 23 Jul 2013).
40. Carlone NA, Borsotto M, Cuffini AM, et al. Effect of fosfo-mycin trometamol on bacterial adhesion in comparison with other chemotherapeutic agents. Eur Urol. 1987;13(Suppl 1):86-91.
41. Kumon H. Management of biofilm infections in the urinary tract. World J Surg. 2000;24(10):1193-6.
42. Marchese A, Gualco L, Debbia EA, et al. In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents. 2003;22(Suppl 2):53-9.
43. Cai Y, Fan Y, Wang R, et al. Synergistic effects of aminogly-cosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. J Antimicrob Chemother. 2009;64(3):563-6.
44. Marchese A, Bozzolasco M, Gualco L, et al. Effect of fosfo-mycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Agents. 2003;22(Suppl 2):95-100.
45. Mikuniya T, Kato Y, Ida T, et al. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Che-mother. 2007;13(5):285-90.
46. Nilsson AI, Berg OG, Aspevall O, et al. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. An-timicrob Agents Chemother. 2003;47(9):2850-8.
47. Suárez JE, Mendoza MC. Plasmid-encoded fosfomycin resistance. Antimicrob Agents Chemother. 1991;35(5):791-5.
48. Arca P, Hardisson C, Suárez JE. Purification of a glutathione S-transferase that mediates fosfomycin resistance in bacteria. Antimicrob Agents Chemother. 1990;34(5):844-8.
49. Li Pira G, Pruzzo C, Schito GC. Monuril and modification of pathogenicity traits in resistant microorganisms. Eur Urol. 1987;13 Suppl 1:92-7.
50. Andreu A, Planells I. Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study [in Spanish]. Med Clin (Barc). 2008;130(13):481-6.
51. Junquera S, Loza y Fernando Baquero E. Changes in the antimicrobial susceptibility of Escherichia coli isolates from noso-comial versus community-acquired urinary tract infections [in Spanish]. Enferm Infecc Microbiol Clin. 2005;23(4):197-201.
52. Lorente Garín JA, Placer Santos J, Salvadó Costa M, et al. Antibiotic resistance transformation in community-acquired urinary infections [in Spanish]. Rev Clin Esp. 2005; 205(6):259-64.
53. Rodríguez López FC, Franco-Alvarez de Luna F, Gordillo Urbano RM, et al. Microorganisms isolated from outpatient urine samples and antimicrobial susceptibility over a 12-year period [in Spanish]. Rev Esp Quimioter. 2005;18(2):159-67.
54. Arzouni JP, Bouilloux JP, de Moüy D, et al. Urinary tract infections in women aged 15 to 65 years in open-care practice: monitoring of Escherichia coli sensitivity to fosfomycin treatment on the basis of the previous history [in French]. Med Mal Infect. 2000;30:699-702.
55. Honderlick P, Cahen P, Gravisse J, et al. Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006? [in French]. Pathol Biol (Paris). 2006;54(8-9):462-6.
56. Oteo J, Orden B, Bautista V, et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother. 2009;64(4):712-7.
57. Rodríguez-Avial C, Rodríguez-Avial I, Hernández E, et al. Increasing prevalence of fosfomycin resistance in extended-spectrum-b- lactamase-producing Escherichia coli urinary isolates (2005-2009-2011) [in Spanish]. Rev Esp Quimiot. 2013;26(1):43-6.
58. Oteo J, Bautista V, Lara N, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum b-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother. 2010;65(11):2459-63.
59. Ungheri D, Albini E, Belluco G. In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fos-fomycin trometamol. J Chemother. 2002;14(3):237-40.
60. Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35(3):240-3.
61. Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum b-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43-50.
62. Neuner EA, Sekeres J, Hall GS, et al. Experience with fosfo-mycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012; 56(11):5744-8.
63. Pogue JM, Marchaim D, Abreu-Lanfranco O, et al. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10. J Anti-biot (Tokyo). 2013. doi:10.1038/ja.2013. 56.
64. Bergan T, Thorsteinsson SB, Albini E. Pharmacokinetic profile of fosfomycin trometamol. Chemotherapy (Basel). 1993;39:297-301.
65. Scaglione F, Cicchetti F, Demartini G, et al. Fosfomycin distribution in the lower urinary tract after administration of fos-fomycin trometamol salt. Int J Clin Pharmacol Res. 1994;14(3): 107-9.
66. Borghi CM, Laveneziana D, Riva A, et al. Concentrazioni nel siero e nel tessuto prostatico di fosfomicina con fosfomicina-trometamolo, nuovo derivato della fosfomicina con elevata biodisponibilità per somministazione orale. Farmaci Terapia. 1986;3(3):216-20.
67. Janknegt R, Hooymans PM, Fabius GTJ, et al. Urinary concentrations of fosfomycin after a single 3 g dose of fosfomycin to elderly nursing-home patients. Pharm World Sci. 1994;16: 149-53.
68. Bergogne-Bérézin E, Muller-Serieys C, Joly-Guillou ML, et al. Trometamol-fosfomycin (Monuril) bioavailability and food-drug interaction. Eur Urol. 1987;13(Suppl 1):64-8.
69. Segre G, Bianchi E, Cataldi A, et al. Pharmacokinetic profile of fosfomycin trometamol (Monuril). Eur Urol. 1987;13(Suppl 1):56-63.
70. Bergan T, Mastropaolo G, Di Mario F, et al. Pharmacokinetics of fosfomycin and influence of cimetidine and metoclopramide on the bioavailability of fosfomycin trometamol. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. Basel: Karger; 1988. p. 157-66.
71. Wilson P, Williams JD, Rolandi E. Comparative pharmacoki-netics of fosfomycin trometamol, sodium fosfomycin and calcium fosfomycin in humans. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. Basel: Karger; 1988. p. 136-42.
72. Bergan T. Pharmacokinetics of fosfomycin. Rev Contemp Pharmacother. 1995;6(2):55-62.
73. Kirby WMM. Pharmacokinetics of fosfomycin. Chemotherapy (Basel). 1977;23(Suppl 1):141-51.
74. Naber KG, Thomas P, Fünfstück R. Fosfomycin trometamol in patients with renal insufficiency and in the elderly. Int Arab J Antimicrob Agents. 2012;2(13). doi:10.3823/707.
75. Ceran N, Mert D, Kocdogan FY, et al. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemother. 2010;16(6):424-30.
76. Rafalskiy V, Khodnevitch L, Malev I. Randomized clinical trial of short-course norfloxacin vs single dose fosfomycin for uncomplicated UTI in region with 10% resistance level of uropathogenic E. coli to fluoroquinolone [abstract no. P1784]. 19th European Congress of Clinical Microbiology and Infectious Diseases; 16-19 May 2009; Helsinki.
77. Gupta K, Hooton TM, Stamm WE. Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother. 2005;56(1):243-6.
78. Stapleton A, Roberts P, Cox M. Pilot study of fosfomycin tro-metamol compared with trimethoprim-sulfamethoxazole for acute uncomplicated cystitis in women [abstract no. 305]. 49th Annual Meeting of the Infectious Diseases Society of America; 20-23 Oct 2011; Boston (MA).
79. Bayrak O, Ç imentepe E, İnegöl I, et al. Is single-dose fosfo-mycin trometamol a good alternative for asymptomatic bacte-riuria in the second trimester of pregnancy? Int Urogynecol J. 2007;18(5):525-9.
80. Estebanez A, Pascual R, Gil V, et al. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect Dis. 2009;28(12):1457-64.
81. Usta TA, Dogan O, Ates U, et al. Comparison of single-dose and multiple-dose antibiotics for lower urinary tract infection in pregnancy. Int J Gynaecol Obstet. 2011;114(3):229-33.
82. Krcmery S, Hromec J, Demesova D. Treatment of lower urinary tract infection in pregnancy. Int J Antimicrob Agents. 2001;17(4):279-82.
83. Harvard Davis R, O'Dowd TC, Holmes W, et al. A comparative double-blind randomised study of single dose fosfomycin tro-metamol with trimethoprim in the treatment of urinary tract infections in general practice. Chemotherapy. 1990;36 Suppl 1:34-6.
84. De Cecco L, Ragni N. Urinary tract infections in pregnancy: Monuril single-dose treatment versus traditional therapy. Eur Urol. 1987;13(Suppl 1):108-13.
85. Crocchiolo P. Single-dose fosfomycin trometamol versus multiple-dose cotrimoxazole in the treatment of lower urinary tract infections in general practice. Chemotherapy. 1990;36(Suppl 1):37-40.
86. de Jong Z, Pontonnier F, Plante P. Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections. Urol Int. 1991;46(4):344-8.
87. Ferraro G, Ambrosi G, Bucci L, et al. Fosfomycin trometamol versus norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly. Chemotherapy. 1990;36(Suppl 1):46-9.
88. Jardin A. A general practitioner multicenter study: fosfomycin trometamol single dose versus pipemidic acid multiple dose. Infection. 1990;18(Suppl 2):89-93.
89. Richaud C. Single dose treatment of lower urinary tract infection in women: results of a trial with fosfomycin trometamol versus pefloxacin [in French]. Med Mal Infect. 1995;25:154-9.
90. Reynaert J, Van Eyck D, Vandepitte J. Single dose fosfomycin trometamol versus multiple dose norfloxacin over three days for uncomplicated UTI in general practice. Infection. 1990; 18(Suppl 2):S77-9.
91. Van Pienbroek E, Hermans J, Kaptein AA, et al. Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women. Pharm World Sci. 1993;15(6):257-62.
92. Minassian MA, Lewis DA, Chattopadhyay D, et al. A comparison between single-dose fosfomycin trometamol (Monuril ) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents. 1998;10(1):39-47.
93. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999;21(11):1864-72.
94. de Andrade J, Lopes CMC, da Silva DC, et al. Fosfomycin trometamol single-dose in the treatment of uncomplicated urinary tract infections in cardiac pregnant or non pregnant women: a controlled study [in Portuguese]. J Bras Ginec. 1994;104(9): 345-51.
95. Moroni M. Monuril in lower uncomplicated urinary tract infections in adults. Eur Urol. 1987;13(Suppl. 1):101-4.
96. Elhanan G, Tabenkin H, Yahalom R, et al. Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women. Antimicrob Agents Chemother. 1994;38(11):2612-4.
97. Boerema JBJ, Willems FTC. Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice. Infection. 1990;18(Suppl 2):S80-8.
98. Cooper J, Raeburn A, Brumfitt W, et al. Single dose and conventional treatment for acute bacterial and non-bacterial dysuria and frequency in general practice. Infection. 1990;18(2):65-9.
99. Neu HC. Fosfomycin trometamol versus amoxycillin: single-dose multicenter study of urinary tract infections. Chemotherapy. 1990;36(Suppl 1):19-23.
100. Zinner S. Fosfomycin trometamol versus pipemidic acid in the treatment of bacteriuria in pregnancy. Chemotherapy. 1990; 36(Suppl 1):50-2.
101. Palmieri G, Palmieri R, Ambrosi G, et al. A new single-dose antibiotic in urinary tract infection tretament in elderly patients. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. Basel: Karger; 1988. p. 322-4.
102. Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a metaanalysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(9):1862-77.
103. Bjerklund Johansen TE, Botto H, Cek M, et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. In: Naber KG, Schaeffer AJ, Heyns CF, editors. Urogenital infections Arnhem: European Association of Urology-International Consultation on Uro-logical Diseases; 2010. p. 980-91.
104. AFSSAPS (Agence française de sécurité sanitaire des produits de santé). AFSSAPS practice recommendations for diagnosis and antibiotic therapy of adult community urinary tract infections [in French]. Med Mal Infect. 2008;38 Suppl 3:S203-52.
105. Denes E, Prouzergue J, Ducroix-Roubertou S, et al. Antibiotic prescription by general practitioners for urinary tract infections in outpatients. Eur J Clin Microbiol Infect Dis. 2012;31(11): 3079-83.
106. Slekovec C, Leroy J, Vernaz-Hegi N, et al. Impact of a region wide antimicrobial stewardship guideline on urinary tract infection prescription patterns. Int J Clin Pharm. 2012;34(2): 325-9.
107. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs. 2009;69(14): 1879-901.
108. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents. 2003;22(Suppl 2):79-83.
109. Naber KG, Wullt B, Wagenlehner FME. Antibiotic treatment of uncomplicated urinary tract infection in premenopausal women. Int J Antimicrob Agents. 2011;38(Suppl):21-35.
110. Nicolle LE. Asymptomatic bacteriuria: to treat or not to treat. In: Naber KG, Schaeffer AJ, Heyns CF, editors. Urogenital Infections. Arnhem: European Association of Urology-International Consultation on Urological Diseases; 2010. p. 303-13.
111. Bailey RR. Single-dose antibacterial treatment for bacteriuria in pregnancy. Drugs. 1984;27(2):183-6.
112. Norwich Pharmaceuticals Inc. Furadantin (nitrofurantoin) oral suspension: US prescribing information; 2008. http://www.accessdata.fda.gov/drugsatfda- docs/label/2009/009175s037lbl. pdf (Accessed 23 Jul 2013).
113. GlaxoSmithKline. Ceftin tablets (cefuroxime axetil tablets) and Cefitin® for oral suspension (cefuroxime axetil powder for oral suspension): US prescribing information; 2007. http://www.accessdata.fda.gov/drugsat fda-docs/label/2007/050605s042lbl. pdf (Accessed 23 Jul 2013).
114. Palou J, Angulo JC, Ramon de Fata F. Randomized comparative study for the assessment of a new therapeutic schedule of fosfomycin trometamol in postmenopausal women with uncomplicated lower urinary tract infection [in Spanish]. Actas Urol Esp. 2013;37(3):147-55.
115. Senol S, Tasbakan M, Pullukcu H, et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother. 2010;22(5):355-7.
116. Pullukcu H, Tasbakan M, Sipahi OR, et al. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents. 2007;29(1):62-5.
117. Rudenko N, Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol: double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung. 2005;55(7):420-7.
118. Mozdzan M, Ruxer J, Siejka A, et al. The efficacy of chronic therapy of recurrent lower urinary tract infections with fosfo-mycin and nitrofurantoin in type 2 diabetic patients. Adv Clin Exp Med. 2007;16(6):777-84.
119. Ongün S, Aslan G, Avkan-Oguz V. The effectiveness of singledose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. Urol Int. 2012;89(4):439-44.
120. Baert L, Billiet I, Vandepitte J. Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection. Infection. 1990;18(Suppl 2):S103-6.
121. Periti P, Novelli A, Reali EF, et al. Prophylactic chemotherapy with fosfomycin trometamol salt during transurethral prostatic surgery: a controlled multicenter clinical trial. Eur Urol. 1987;13(Suppl 1):122-31.
122. di Silverio F, Ferrone G, Carati L. Prophylactic chemotherapy with fosfomycin trometamol during transurethral surgery and urological manoeuvres: results of a multicentre study. Infection. 1990;18(Suppl 2):S98-102.
123. Di Silverio F, Cruciani E, Ferrone G, et al. Evaluation of fos-fomycin trometamol in the prevention of urinary tract infection after ESWL and ureteropyeloscopy. In: Neu HC, Williams JD, editors. New trends in urinary tract infections. Basel: Karger; 1988. p. 329-32.
124. Billiet I, Baert L, Vandepitte J. Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection. Infection. 1990;18(Suppl 2):S103-6.
125. Novelli A, Reali EF, Lamanna S, et al. Chemoprevention using fosfomycin trometamol in transurethral resection of the prostate: multicenter controlled clinical study [in Italian]. Ann Ist Super Sanita. 1987;23(4):809-12.
126. Caramalli S, Amprimo MC, Cavalli G, et al. Effect and phar-macokinetics of netilmicin given as bolus intramuscular administration: an open comparative trial versus amikacin and fosfomycin in elderly patients affected by urinary tract infections. Int J Clin Pharmacol Res. 1991;11(2):55-65.
127. Careddu P, Borzani M, Varotto F, et al. Trometamol salt of fosfomycin (Monuril): preliminary pharmacokinetic and clinical experience in the treatment of urinary tract infections in children. Eur Urol. 1987;13(Suppl 1):114-8.
128. Varese LA. Trometamol salt of fosfomycin versus netilmicin: randomized multicenter study in children's lower urinary tract infections. Eur Urol. 1987;13(Suppl 1):119-21.
129. Principi N, Corda R, Bassetti D, et al. Fosfomycin trometamol versus netilmicin in children's lower urinary tract infections. Chemotherapy. 1990;36(Suppl 1):41-5.
130. Careddu P, Borzani M, Scotti L, et al. Treatment of lower urinary tract infections in children: single dose fosfomycin tro-metamol versus pipemidic acid. Chemioterapia. 1987;6(4): 290-4.